lansoprazole has been researched along with Colitis in 12 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "To clarify the effector sites of lansoprazole in the colonic mucosa during the formation of colitis, dextran sulfate sodium-induced colitis was induced by the oral administration of 3% aqueous solution for 3 and 7 days." | 7.73 | Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. ( Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T, 2005) |
| "To clarify the microvascular changes and the effector sites of lansoprazole during the formation of colitis, the dextran sulfate sodium (DSS)-induced colitis was induced by the oral administration for 3 and 7 days." | 7.73 | Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. ( Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K, 2006) |
| "A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole." | 7.71 | Collagenous colitis associated with lansoprazole. ( Mattia, A; Wilcox, GM, 2002) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 7.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 5.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 5.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "To clarify the effector sites of lansoprazole in the colonic mucosa during the formation of colitis, dextran sulfate sodium-induced colitis was induced by the oral administration of 3% aqueous solution for 3 and 7 days." | 3.73 | Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. ( Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T, 2005) |
| "To clarify the microvascular changes and the effector sites of lansoprazole during the formation of colitis, the dextran sulfate sodium (DSS)-induced colitis was induced by the oral administration for 3 and 7 days." | 3.73 | Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. ( Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K, 2006) |
| "A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole." | 3.71 | Collagenous colitis associated with lansoprazole. ( Mattia, A; Wilcox, GM, 2002) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 3.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "Colitis was induced with less C." | 1.48 | Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria. ( Adachi, S; Azuma, T; Fukuda, S; Hoshi, N; Inoue, J; Ishida, T; Kong, L; Ku, Y; Ooi, M; Otsuka, T; Tsukimi, T; Watanabe, D; Yamairi, H; Yasutomi, E; Yoshida, M, 2018) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 1.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 1.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Páramo-Zunzunegui, J | 1 |
| Ortega-Fernandez, I | 1 |
| Benito-Barbero, S | 1 |
| Rubio-López, L | 1 |
| Gandhi, T | 1 |
| Sharma, A | 1 |
| Vyas, N | 1 |
| Gupta, P | 1 |
| Parikh, M | 1 |
| Shah, H | 1 |
| Yasutomi, E | 1 |
| Hoshi, N | 1 |
| Adachi, S | 1 |
| Otsuka, T | 1 |
| Kong, L | 1 |
| Ku, Y | 1 |
| Yamairi, H | 1 |
| Inoue, J | 2 |
| Ishida, T | 1 |
| Watanabe, D | 1 |
| Ooi, M | 1 |
| Yoshida, M | 1 |
| Tsukimi, T | 1 |
| Fukuda, S | 1 |
| Azuma, T | 1 |
| Bardet, R | 1 |
| Moreno, JP | 1 |
| Rodriguez, T | 1 |
| Trémeau, AL | 1 |
| Hernandez, É | 1 |
| Bolot, AL | 1 |
| Thomson, RD | 1 |
| Lestina, LS | 1 |
| Bensen, SP | 1 |
| Toor, A | 1 |
| Maheshwari, Y | 1 |
| Ratcliffe, NR | 1 |
| Mukherjee, S | 1 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Nakamura, M | 2 |
| Asada, M | 2 |
| Atsuda, K | 1 |
| Matsui, H | 2 |
| Watanabe, T | 1 |
| Higuchi, K | 1 |
| Arakawa, T | 1 |
| Hibi, N | 2 |
| Tsuchimoto, K | 2 |
| Oda, M | 1 |
| Ghilain, JM | 1 |
| Schapira, M | 1 |
| Maisin, JM | 1 |
| De Maeght, S | 1 |
| Piron, A | 1 |
| Gerard, R | 1 |
| Henrion, J | 1 |
| Wilcox, GM | 1 |
| Mattia, A | 1 |
| Macaigne, G | 1 |
| Boivin, JF | 1 |
| Simon, P | 1 |
| Chayette, C | 1 |
| Cheaib, S | 1 |
| Deplus, R | 1 |
12 other studies available for lansoprazole and Colitis
| Article | Year |
|---|---|
Eosinophilic colitis: an infrequent disease with difficult diagnose.
Topics: Aged, 80 and over; Biopsy; Colitis; Colon; Colonoscopy; Cromolyn Sodium; Drug Therapy, Combination; | 2020 |
Lansoprazole a Proton Pump Inhibitor Prevents IBD by Reduction of Oxidative Stress and NO Levels in the Rat.
Topics: Animals; Colitis; Colon; Female; Inflammatory Bowel Diseases; Lansoprazole; Nitric Oxide; Oxidative | 2021 |
Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria.
Topics: Animals; Citrobacter rodentium; Colitis; Disease Models, Animal; Enterobacteriaceae Infections; Lans | 2018 |
[A resistant diarrhea].
Topics: Aged, 80 and over; Anti-Ulcer Agents; Antidepressive Agents; Antidiarrheals; Colitis; Comorbidity; D | 2016 |
Lansoprazole-associated microscopic colitis: a case series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Colitis; Co | 2002 |
Diarrhea associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastroin | 2003 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Infective Agents; Apoptosis; Autoradiography; | 2005 |
Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Binding Sites; Capillary Permeability; Colitis; Cy | 2006 |
[lymphocytic colitis associated with lansoprazole treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Diarrhea; Humans; Intestinal Mu | 2000 |
Collagenous colitis associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Collagen; Female; Humans; Lanso | 2002 |
[Lansoprazole-associated collagenous colitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Colitis; Collagen; Female; Gastroesophageal Reflux; | 2001 |